Suchergebnisse - "Cook, Gordon"

PubPharm (30)

1

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2023

von Mateos, M. | Rigaudeau, S. | Basu, S. | +14

2

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

3

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

enthalten in: Blood | 2022

von San-Miguel, J. | Avet-Loiseau, H. | Paiva, B. | +24

CommentIn: Blood. 2022 Jan 27;139(4):469-471. - PMID 35084473

4

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes : Results from 3894 Patients in the Myeloma XI Trial

enthalten in: Clinical lymphoma, myeloma & leukemia | 2021

von Bird, S. | Cairns, D. | Menzies, T. | +12

5

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15

6

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

7

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+) : Interim analysis of an open-label randomised controlled trial

enthalten in: PLoS medicine | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

8

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

enthalten in: Blood cancer journal | 2020

von Kaufman, J. | Dimopoulos, M. | White, D. | +26

9

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

enthalten in: Blood | 2020

von Craig, Z. | Cook, G. | Pawlyn, C. | +13

CommentIn: Blood. 2020 Aug 27;136(9):1019-1021. - PMID 32853375

10

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : extended follow-up of POLLUX, a randomized, open-label, phase 3 study

enthalten in: Leukemia | 2020

von Bahlis, N. | Dimopoulos, M. | White, D. | +16